Neuropathic Pain Market Growth, Business Prospects And Forecast To 2023


The regional market would be dominated by the US and Canada as their financial state is better than most of the provinces.

Neuropathic Pain Market Overview:

Neuropathic pain can be discussed as a chronic type of pain that may occur due to tissue injury and has a link with sensory-motor system. This market for neuropathic pain is getting traction from various factors like rising prevalence of diabetic neuropathy, increasing healthcare expenditure, major increase in number of adult populations recording changes for such cases, and others within the region and Increasing healthcare expenditure may also play a significant role in taking the market forward.

The Neuropathic Pain Market may find a heightened interest in a CAGR of 6.06% and this can assist the market in surpassing a valuation of USD 8,017.43 Million between 2018 and 2023, which can be taken as the forecast period. Market Research Future (MRFR), in their analytical study of the global market for neuropathic pain, made revelations regarding factorial details based on their market impact in the period.

Regional Analysis:

The Americas market is a combination of reports from North America and South America, and it is growing rapidly due to superior infrastructure, better funding, and higher technological integration. The market can gain substantially from rising awareness and higher expenditure capacity. The regional market would be dominated by the US and Canada as their financial state is better than most of the provinces. Europe would record similar growth, which can bank much on the contributions made in the research and development sector.

The Asia Pacific market would witness high growth possibilities due to huge market population and increasing investment made by emerging economies. Japan, India, China, and others can contribute to the growth significantly.


The global market for neuropathic pain, as registered in the report published by MRFR, includes indication, type, treatment, distribution channel, diagnosis, and end user as segments that can bring out insights regarding the market. This would also make the study of the market easier for various companies.

By type, the market report on neuropathic pain includes entrapment neuropathy, peripheral neuropathy, postherpetic neuralgia (PHN), trigeminal neuralgia, phantom limb pain, and post-traumatic neuropathy.

By indication, the market for neuropathic pain includes spinal stenosis, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and others.

By diagnosis, the market for neuropathic pain comprises imaging physical examination and blood tests. The imaging market segment would include MRI, electromyography, and CT.

Competitive Landscape:

A number of companies are taking active part in the global market for neuropathoc pain. These companies can witness significant traction by implementing strategic moves. These tactical moves can ensure better CAGR for these companies and take the market forward by leaps and bounds. MRFR registered and profiled a few companies that can influence and inspire future market study. These companies are Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Depomed Inc. (U.S.), BJohnson Johnson Services Inc. (U.S.), axter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), Astellas Pharma Inc. (Tokyo), GlaxoSmithKline plc (U.K.), Sanofi S.A. (France), Biogen Inc. (U.S.), and Abbott Laboratories (U.S.). 




193 Blog posts